Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether taking vitamin C can help reduce long-lasting pain after knee replacement surgery, known as total knee arthroplasty. It's a Phase II study, meaning it's still in the early stages of testing and aims to find out if a larger study can be done in the future. The trial is currently recruiting participants aged 65 to 74 who are having knee replacement surgery due to severe arthritis. To join, participants must be over 18 and not have certain health issues like kidney stones or ongoing infections.
If you or a loved one qualifies and decides to participate, you will be randomly assigned to receive either vitamin C or a placebo (a substance with no active effect) to see how it affects pain levels after surgery. Participants will need to attend follow-up appointments and complete some questionnaires to track their progress. It's important to note that the study is designed to ensure safety and gather useful information about vitamin C's potential benefits for pain management after knee surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients \>18 years old
- • Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee
- Exclusion Criteria:
- • TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis
- • History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency
- • Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town)
- • Language difficulties that would impede valid completion of questionnaires
- • Planned staged bilateral TKA
- • Treating surgeon deems patient inappropriate for inclusion in trial
- • Any allergy or sensitivity to milk
- • Pregnant or planning to become pregnant during the study
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
James Khan, MD
Principal Investigator
University Health Network; Department of Anesthesia and Pain Medicine
Raman Mundi, MD
Principal Investigator
Holland Orthopedic and Arthritic Centre
Harman Chaudhry, MD
Principal Investigator
Holland Orthopedic and Arthritic Centre
Jesse Wolfstadt, MD
Principal Investigator
Mount Sinai Hospital; Department of Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported